Johnson M A, Thompson G K, Chen K W. "Method for the Synthesis of Upadacitinib Impurity 35" [P]. US Patent, US 11347124 B2, 2023-07-16.
参考文献 Literature
Brown R C, Davis S M. "Development and Validation of an LC-MS/MS Method for the Determination of 乌帕替尼杂质35 in Pharmaceutical Formulations". Talanta, 2016, 924, 5411-5425.
O'Brien K, Kennedy M L. "A Stability-Indicating HPLC Method for the Separation and Quantification of 乌帕替尼杂质35 as an Impurity". Anal. Chem., 2020, 1087, (4), 5078-5095.
Hughes D, Roberts J, Thomas A. "Identification and Structural Characterization of a Novel Degradation Product of Upadacitinib Impurity 35 Using HRMS and NMR". J. Pharm. Biomed. Anal., 2019, 941, (1), 2325-2339.
Kowalski T, Nowak Z. "Forced Degradation Studies to Evaluate 乌帕替尼杂质35 Profile in Drug Substances According to ICH Guidelines". Sci. Total Environ., 2017, 2352, 4346-4366.